BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q4 2022 Earnings Call Transcript

Gena Wang: Thank you for taking my questions. The first one is regarding 10013. So, just want to confirm, is it fair to say that we should not expect the FDA clinical hold regarding this program? And then my second question is regarding the ORLADEYO. In early January, you mentioned that the retention rate is about 60%. Can you clarify if that is 1 year or three months retention rate? And also, do you expect the similar retention rate maintaining in 2023?

Helen Thackray: So, the first question on 10013, we are not on clinical hold with this program. There is €“ it’s a little difficult to say what will happen in the future. So, that’s where we are today.

Anthony Doyle: And as far as the patient retention, Gena, yes, 60% of that 1 year and we would expect €“ what we are seeing in the overall retention rate is really stabilizing out. And so that’s part of our confidence, less than $320 million this year. And so we would expect the same retention trend overall in 2023.

Gena Wang: Thank you.

Operator: Our last question comes from Rohit Bhasin of Needham & Co. Please go ahead.

Rohit Bhasin: This is Rohit on for Serge. Thanks for taking our questions. Just in terms of peak sale estimates, do you still expect about 20% to 25% to come from ex U.S. territories? And can you talk about your expectations for the long-term competitive landscape for ORLADEYO. Thanks.

Charlie Gayer: Sure. Hey Rohit. Absolutely, so when we talk about the $1 billion, we still see about 20% of that is coming from Europe and the rest of the world and all the trends in those €“ in the 15 countries where we have launched so far, give us confidence that we will get to that 20%…

Jon Stonehouse: And then with regard to the competitors, it’s a pretty crowded space, but with regard to oral specifically, it’s been challenging for some to advance their programs. And so what that means for us is we have more time to get people to try our drug and see if it works for them. And what we have learned in the marketplace is to get people to switch, there has got to be some meaningful benefit that they are not seen with the drug that they are on. And it can’t be efficacy because if you are on our drug, you are controlled, if you are not controlled, you are not staying on our drug. So €“ and so that goes for injectables as well. And I think a tailwind that we are curious, Charlie, has pointed this multiple times, but we will be curious to see is as new products come to market, if a physician is saying, hey, maybe I will switch from one injectable to another, why wouldn’t they try an oral first.

And then if it didn’t work for that patient, switch to the new injectables. So, it could be a tailwind.

Rohit Bhasin: Thank you.

Jon Stonehouse: You’re welcome.

Operator: This concludes the question-and-answer session. The conference has now also concluded. Thank you for attending today’s presentation and you may now disconnect.